DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Mikael Dolsten - 5 Pfizer's - 2 Eli Lilly - 2 Michael Erman - 2 Albert Bourla - 1 Bourla - 1 Dolsten - 1 Wall - 1
Top related locs:
U.S Bengaluru Covid Bothell , Washington biologics China Eagle Rock , California York
Top related orgs:
Pfizer - 5 Novo Nordisk - 2 Drug Administration - 2 Thomson - 2 U.S - 1 Nurphoto - 1 Getty - 1 Astellas Pharma - 1

Search resuls for: "Dolsten"


7 mentions found


☆ Pfizer moves forward with once-daily version of weight loss pill after setbacks
  + stars: | 2024-07-11 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Pfizer on Thursday said it will move forward with a once-daily version of its weight loss pill, danuglipron, after it saw "encouraging" data in an ongoing early-stage trial. Pfizer is one of several drugmakers racing to win a slice of the market for a highly popular class of weight loss and diabetes drugs called GLP-1 agonists. At the time, the pharmaceutical giant said phase one trial data on the once-daily version would "inform a path forward." Pfizer's danuglipron is a GLP-1 that promotes weight loss in the same way as Novo Nordisk' s injection Wegovy and diabetes treatment Ozempic. But he said Pfizer was looking for potential licensing deals or earlier-stage weight loss drugs.
Persons: Albert Bourla, Pfizer's, Eli Lilly, Bourla, Mikael Dolsten, Dolsten Organizations: Pfizer, Novo Nordisk, U.S
☆ Pfizer is betting big on cancer drugs to turn business around after Covid decline – here's what to know
  + stars: | 2024-03-10 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +13 min
Now, the company is betting on cancer drugs to help it regain its footing after a rocky year marked by the rapid decline of its Covid business. That $43 billion Seagen acquisition doubled Pfizer's oncology drug pipeline to 60 different experimental programs. Some analysts noted that it might take a few years for some of Pfizer's cancer drugs in mid-stage development to show pivotal clinical trial data and become less risky. Revenue from the blockbuster breast cancer drug Ibrance and prostate cancer treatment Xtandi, which Pfizer shares with Astellas Pharma, has declined over the past year. They are among the most expensive prescription drugs in the U.S. Before the Seagen deal, 94% of Pfizer's cancer products were small-molecule drugs.
Persons: Wall, Seagen, Chris Boshoff, Boshoff, David Ryder, Trung Huynh, Joe Biden's, Chris Schott, Suneet Varma, RemeGe, Merck, Padcev, Guggenheim, Pfizer's, Pfizer hasn't, Dr, Mikael Dolsten, Irfan Khan Organizations: Nurphoto, Getty, Pfizer, Astellas Pharma, Guggenheim, Bloomberg, UBS, Medicare, Drug Administration, FDA, ADC, JPMorgan, Drugs, CNBC, CVS Pharmacy, Los Angeles Times Locations: Covid, Bothell , Washington, U.S, biologics, China, Eagle Rock , California
☆ Pfizer Nixes More Study of Twice-Daily Obesity Pill Treatment That Made Many Patients Nauseous
  + stars: | 2023-12-01 | by ( Associated Press | Dec. | At A.M. | ) www.usnews.com   time to read: +2 min
Pfizer shares sank Friday when the drugmaker said it would abandon a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taking it. But Novo and Pfizer are also trying to develop pill versions that would be easier for patients to take. Pfizer said it saw patient discontinuation rates topping 50% across all doses in a mid-stage study of twice-daily danuglipron. It ranged from nearly 7% to more than 11% in patients taking the pills. By comparison, obese patients without diabetes lost about 18% of their weight compared to a placebo when taking taking Eli Lilly’s Zepbound in late-stage research.
Persons: Eli Lilly, Eli Lilly’s Zepbound, Mikael Dolsten Organizations: Pfizer, Novo Nordisk, Novo, Drug Administration, Pfizer Inc Locations: York
☆ Pfizer drops plan to study twice-daily obesity pill in late-stage studies
  + stars: | 2023-12-01 | by ( ) www.reuters.com   time to read: +2 min
A person walks past the Pfizer Headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020. Pfizer said it would instead focus on a once-daily, modified release version of danuglipron and "gathering the data to understand its potential profile". In the current study of the twice-daily version, Pfizer said the drug, however, met the main goal of reducing weight in adults with obesity and without type 2 diabetes. Pfizer said while the common side effects in the twice-daily version study were mild, it saw high rates of those events in the trial. However, no new safety signals were observed in the study, Pfizer said.
Persons: Carlo Allegri, danuglipron, Eli Lilly's, Mikael Dolsten, Pfizer, Manas Mishra, Michael Erman, Shinjini Organizations: Pfizer, REUTERS, Zepbound, Thomson Locations: Manhattan, New York City , New York, U.S, Bengaluru, New York
☆ Pfizer, Flagship Pioneering to invest $100 mln in drug discovery
  + stars: | 2023-07-18 | by ( ) www.reuters.com   time to read: +2 min
July 18 (Reuters) - U.S. drugmaker Pfizer (PFE.N) and venture firm Flagship Pioneering on Tuesday said they would invest $100 million together to develop up to 10 new potential drugs for areas including internal medicine, oncology, infectious diseases and immunology. Flagship, which has incubated biotech companies, most famously Moderna Inc (MRNA.O), and Pfizer will each invest $50 million. Flagship's drug discovery initiative Pioneering Medicines will lead the exploration process. Paul Biondi, president of Flagship's Pioneering unit and a former top Bristol Myers Squibb (BMY.N) executive, said the partnership will take advantage of Flagship's abilities to develop novel technologies towards bigger disease areas. Drug developers such as Denali Therapeutics (DNLI.O), Foghorn Therapeutics (FHTX.O) and Sana Biotechnology (SANA.O) are some of the other companies backed by Flagship.
Persons: Paul Biondi, Biondi, Mikael Dolsten, Foghorn, Bhanvi, Michael Erman, Shilpi Majumdar, Alexandra Hudson Organizations: drugmaker Pfizer, Moderna Inc, Pfizer, Flagship's, Bristol Myers Squibb, Flagship, Therapeutics, Foghorn Therapeutics, Sana Biotechnology, Alexandra Hudson Our, Thomson Locations: Bengaluru, New Jersey
☆ Here’s what Pfizer and Moderna say is next for their Covid vaccines
  + stars: | 2023-05-22 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +9 min
Scott Olson | Getty ImagesThree years and billions of Covid vaccinations into the pandemic, Pfizer and Moderna say their work is far from over. Here's what Moderna and Pfizer say is next for their Covid shots. Annual Covid shotsPfizer and Moderna aim to keep up with a shift in the U.S. toward annual Covid shots rather than frequent booster doses. Miller, who helped lead the development of Moderna's Covid shot in 2020, said the advantages of using mRNA became evident earlier on in the pandemic. 'Next-generation' Covid shotsPfizer's and Moderna's Covid vaccines both deliver robust protection against the virus, but that immunity can start to fade after four to six months.
☆ How a gene-editing breakthrough from a Harvard lab saved the life of a girl with leukemia
  + stars: | 2022-12-19 | by ( Andrew Dunn | ) www.businessinsider.com   time to read: +6 min
A 13-year-old girl was the world's first patient to get a cell therapy called base editing in May. Base editing is a new gene-editing technology that could lead to cures for many diseases. Alyssa, 13, was the first-ever patient to receive a base-edited cell therapy after enrolling in a clinical trial in May. Base editing allows scientists to make ultraprecise changes to single letters of DNA in cells. Alyssa, a teenager in Leicester, England, received a base-edited cell therapy to treat her leukemia.
0 next >>
Total: 7